Objective: Importance of endothelin in mediating the chronic renal alterations of chronic heart failure was studied in rats chronically treated with bosentan after myocardial infarction. Methods: Rats were subjected to coronary artery ligation and were treated for 8 weeks with placebo or bosentan, a dual ET and ET receptor antagonist, (|100 mg / kg / day) as food admix. Sham-operated rats served as A B normal controls. Cardiac and renal functions were measured at the end of 8-week treatment. Results: Bosentan significantly reduced the elevated left ventricular end-diastolic pressure (from 26.663.3 to 11.462.2 mmHg, P,0.001) and the increased heart-to-body-weight ratio seen in untreated rats with myocardial infarction. Bosentan prevented the marked increase in renal vascular resistance (bosentan, 7.760.6; untreated, 15.662.5 mmHg / ml / min; P,0.001). This led to a significant increase in renal plasma flow resulting in a decrease in filtration fraction. Bosentan furthermore increased urinary sodium excretion. Conclusions: Prolonged ET receptor blockade in rats with myocardial infarction has chronic renal vasodilatory effect and improves renal sodium excretory function. Thus, dual ET antagonists such as bosentan might be useful in the treatment of the progressive renal failure associated with human chronic heart failure.
Introduction
ET-1 concentration and a blunted renal response to ET-1 have been reported in experimental CHF [6] [7] [8] . Acute ET Chronic heart failure (CHF) is characterized by left receptor blockade improves RBF in experimental CHF, as ventricular (LV) dysfunction, increased renal vascular measured by Doppler flowmeter [7, 9] . resistance (RVR), sodium retention and neurohormonal
We recently found that acute ET receptor blockade with activation [1, 2] . There is evidence to suggest that endoa dual parenteral ET receptor antagonist, tezosentan [10] , thelin (ET) may be involved in the pathophysiology of in rats with CHF induced by myocardial infarction (MI) renal dysfunction associated with CHF. The kidney is one reversed the profoundly increased RVR and improved of the organs that is most sensitive to the profound renal plasma flow and sodium excretion [11] . Therefore, vasoconstrictor effects of exogenously administered ET activation of the endogenous ET system appears to contrib- [3, 4] . Administration of exogenous ET-1 at concentrations ute to the renal vasoconstriction and sodium retention seen mimicking those observed in CHF constricts the renal in CHF. Chronic selective ET receptor antagonism has A vasculature, resulting in an increase in RVR and a decrease been reported to suppress plasma atrial natriuretic peptide, in renal blood flow (RBF) [4, 5] . An elevation in local renal attenuate the magnitude of sodium retention, and prevent the decline in creatinine clearance in experimental CHF [12, 13] . The goal of the present study was to evaluate the effects of chronic dual ET / ET receptor blockade on rats (Sham, n59) were used as controls. Treatment was A B renal alterations in CHF. given as food admix (120 mg bosentan per 100 g powFor this purpose, the effects of long-term ET receptor dered food). Food intake was monitored daily and body blockade with the dual ET receptor antagonist bosentan weights were measured twice a week throughout the 8-were assessed on renal hemodynamics and renal function week period. The average bosentan intake was 9366 in experimental CHF. Accordingly, we measured the mg / kg body weight per 24 h during the second week and effects of chronic bosentan treatment on cardiac and renal remained constant over time in individual animals. The hemodynamics, as well as on 24-h urinary sodium excreaverage dose of bosentan of 100 mg / kg / day was chosen tion in rats with CHF following MI.
as the maximally effective dose on the basis of in vivo pharmacology studies by Clozel et al. [15] . At week 8, the rats were placed in individual metabolic cages overnight. Food but not water was withdrawn from the metabolic 2. Methods cages. Total urine volume was collected for determination of urinary sodium concentration, and 24-h urinary sodium Studies were conducted on 33 male Wistar rats weighing excretion was calculated. 220-260 g (supplied by the Experimental Animal Center of Chinese Academy of Sciences, Shanghai, China, Grade II, Certificate No. 9904). All rats were housed in climate-2.3. Measurements of cardiac and renal hemodynamics controlled conditions with a 12-h light-dark cycle and free access to normal rat chow and drinking water. The animals
The cardiac hemodynamic and renal clearance experiwere handled according to the Position of the American ments were conducted as follows. Rats were anesthetized Heart Association on Research Animal Use adopted with 100 mg / kg, i.p. thiobutabarbital-Na (Inactin, BykNovember 11, 1984, by the American Heart Association.
Gulden, Konstanz, Germany) and placed on a thermostatically controlled heating table to maintain body tem-2.1. Induction of myocardial infarction perature at 36-38 8C. A tracheotomy tube was put in place and a catheter was inserted into the left femoral vein for Myocardial infarction (MI) was produced by a method infusion of synthetic plasma, inulin and p-aminohippurate described elsewhere [14] . In brief, rats were anesthetized (PAH). A polyethylene cannula was placed in the lefẗ with a mixture of ketamine (Ketosol-100, Staub, Bern, femoral artery and connected to a pressure transducer Switzerland) and xylazin (Rompun 2%, Bayer, Lever-(MLT1050 precision BP transducer, AD Instruments, kusen, Germany) (50 mg / 5 mg per kg, intraperitoneally).
Hastings, UK) for recording of arterial blood pressure (BP) The trachea was intubated with a small metal cannula and periodic sampling of blood. The right carotid artery (20-G) and the rats mechanically ventilated with room air was cannulated with a high-fidelity microtip 2F catheter by means of a small rodent ventilator (Model 7025 Rodent (SPR-249, Millar Instruments, Houston, TX, USA) that Ventilator, Hugo Sachs Elektronik, March-Hugstetten, was inserted through the aorta into the left ventricle (LV) Germany) at a rate of 60 cycles / min and a tidal volume of to continually record LV pressure, heart rate (HR) and the 1 ml / 100 g body weight. A left thoracotomy was permaximal rate of rise of LV pressure (dP/dt ). All max formed, and the heart was exposed. The left coronary tracings (LV pressure, BP, HR, mean arterial pressure and artery was ligated with a 6-0 silk suture approximately 2 dP/dt) were recorded on a computer using a PowerLab mm from its origin between the pulmonary artery outflow system. The data acquisition system consisted of a Powertract and the left atrium. Then the chest was closed in three Lab (ML780 PowerLab / 8s and ML118 Quad amplifiers, layers (ribs, muscles and skin). The air within the thorax AD Instruments, Hastings, UK) which was connected to an was removed, allowing the rats to resume spontaneous HP Pavilion 8565C computer with the CHART software respiration. The sham-operated rats were subjected to the (version 3.4, AD Instruments). Through a small, supsame procedure, except that the coronary artery was not rapubic incision, a flanged catheter was placed in the ligated. The rats were allowed to recover from the anesurinary bladder for collection of urine. During surgery, the thesia and were then returned to their cages. The 24-h rat received an intravenous infusion of 1 ml synthetic postoperative mortality rate was about 15% for the infarcplasma and a 0.5 ml bolus of 0.9% NaCl containing 40 tion group. mg / ml inulin (Sigma, St. Louis, MO, USA) and PAH (0.5%, Merck Sharp & Dohme, West Point, PA, USA).
Experimental protocols
Subsequently, a continuous intravenous infusion of 0.9% NaCl containing the same concentrations of inulin and Twenty-four hours after ligation, infarcted rats were PAH at a rate of 10 ml / min / 100 g body weight was randomized to receive either placebo (untreated, Veh-CHF, initiated. After a 45-min equilibration period, renal clearn511) or bosentan (Bos-CHF, n513) for 8 weeks, and ance experiments were begun in which two consecutive were housed individually. Nine untreated sham-operated 20-min urine collections were performed, with midpoint Myocardial infarction-induced CHF rats received placebo (vehicle, CHF1veh) or bosentan (CHF1bos, 100 mg / kg / day as food admix) for 8 weeks. Untreated sham-operated rats (Sham) were used as controls. BW, body weight; CHF, chronic heart failure; HW:BW, heart-to-body-weight ratio; RV:BW, right-ventricular-to-body-weight ratio; LV1S:BW, left-ventricle-plus-septum-to-body-weight ratio. Z *, P,0.05; **, P,0.01; ***, P,0.001 vs. Sham; , P,0. 05; CHF1bos vs. CHF1veh.
arterial blood samples (|150 ml). Blood was centrifuged, Hitachi 7150, Japan). Inulin concentrations in urine and plasma was kept for analysis (see below).
plasma were determined using the anthrone methods [16, 17] . PAH concentrations in urine and plasma were 2.4. Morphometric evaluation of infarct size measured colorimetrically, as described elsewhere [18] . These measurements allowed calculation of inulin clearOn completion of the hemodynamic experiments, the ance (equal to glomerular filtration rate, GFR), PAH rats were killed by exsanguination. The heart was removed clearance (equal to renal plasma flow (RPF) when factored and weighed. The right and left ventricle were dissected for renal extraction of PAH), renal vascular resistance and weighed. The left ventricle, including the interven-(RVR), filtration fraction (FF) and urinary excretion of tricular septum, was fixed in 10% buffered formalin. The sodium (U V). The calculations have been described Na left ventricles were cut from apex to base into four elsewhere [19] [20] [21] . The results of the two clearance transverse segments. The middle two segments, representperiods were averaged. ing the bulk of the left ventricle, were embedded in paraffin, sectioned, and stained. Four slices from these 2.6. Statistical analysis segments were projected onto a screen for morphometry. The entire length of the endocardial circumference and the Data are expressed as mean6S.E.M. Statistical analyses segment of the endocardial circumference made by the were done by analysis of variance (ANOVA) using STATISinfarcted segment of each of the four slices of the LV were TICA (Statsoft) to assess differences in parameters between measured. The entire length of the epicardial circumfergroups. Significant differences were then subjected to postence and the segment of the epicardial circumference made hoc analysis using the Student-Newman-Keuls procedure. by the infarcted segment of each of the four slices of the Statistical significance is defined where P,0.05. LV were measured. These were then averaged for each of the four slices. The fraction of infarcted ventricle was calculated as the average of the four slices expressed as a 3. Results percent of the length of the circumference.
Characterization of myocardial infarction-induced 2.5. Chemical analyses chronic heart failure
Urine volume was measured gravimetrically, and urine Data for heart weight, blood pressure and cardiac was analyzed for sodium, inulin, and PAH concentrations.
hemodynamics at the end of the 8-week treatment are Sodium concentrations in urine were measured using an summarized in Tables 1 and 2 . Coronary artery ligation ion-selective electrode (Automatic Biochemical Analyzer, produced extensive MI with an infarct size of 4362% of Table 2 Effects of chronic bosentan treatment on blood pressure and cardiac hemodynamics in rats with chronic heart failure after myocardial infarction ated rats (Table 1) . 4.360.3 mmHg in control rats, P,0.001) and by signifiAs shown in Fig. 1 , the renal hemodynamics of uncant decreases in the maximal rate of rise of LV pressure treated CHF rats were characterized by a profound eleva-(dP/dt ) (55%) and mean arterial pressure (MAP) tion in RVR, leading to a marked decrease in RPF but a max (22%), when compared to the sham-operated rats. In CHF proportionately lesser decline in GFR. Thus, the filtration rats, heart and right ventricular weights increased sigfraction rose. Urine flow-rate was lower in CHF rats (data nificantly compared to sham-operated rats. There was no not shown) and sodium excretion (U V) as measured Na change in body weight (BW) but a significant increase was during clearance periods was significantly lower in CHF observed in heart weight:body weight (HW:BW), right rats, as compared to the sham group. The 24-h U V was Na Fig. 1 . Renal hemodynamic parameters, glomerular filtration rate and urinary sodium excretion measured in anesthetized CHF rats treated or not with bosentan and compared to sham-operated rats, GFR, glomerular filtration rate; RPF, renal plasma flow; RVR, renal vascular resistance; U V, urinary Na sodium excretion; CHF, chronic heart failure; veh, vehicle; bos, bosentan *, P,0.05; ***, P,0.001. 
Discussion
The rat model of coronary artery ligation is a well characterized model of CHF that shares many features with congestive heart failure in humans. In the present study, in which hemodynamic measurements were made at 8 weeks after coronary artery ligation, depressed cardiac performance in the untreated MI rats was documented by a profound increase of LVEDP with a mean value of exceeding 26 mmHg, mild hypotension and significant decrease in cardiac contractility (dP/dt ). This hemomax dynamic abnormality was associated with large infarct and left ventricular hypertrophy. These findings indicate that relatively severe CHF occurred in these animals, a condition typically associated with compromised renal function and sodium retention [22] [23] [24] . Fig. 2 . Twenty-four hour urinary sodium excretion in awake CHF rats Indeed, we found that in this study, untreated CHF rats treated or not with bosentan and compared to sham-operated rats, U V, Na urinary sodium excretion; CHF, chronic heart failure; veh, vehicle; bos, exhibited profound renal vasoconstriction associated with a bosentan *, P,0.05; ***, P,0.001. large fall in RPF and a decline in GFR, resulting in a significant rise in FF. Also, the CHF rats had impaired renal ability to excrete sodium. Our findings are in also markedly lower in untreated CHF rats (Fig. 2 ) than in agreement with previously reported studies from other sham-operated animals (0.25360.043 vs. 0.86760.070 laboratories [22] [23] [24] [25] . Whole kidney GFR is minimally mmol / 24 h, P,0.001).
affected in mild to moderate CHF, but RPF and GFR are decreased, and FF is increased in severe CHF [1, 25] .
Effects of chronic bosentan treatment in rats with
Although the present study was not designed to eluci-CHF after MI date the renal microcirculatory changes in CHF, the elevated FF does suggest altered glomerular hemodyAfter 8 weeks of treatment, bosentan tended to increase namics in CHF. A small number of previous reports have survival: 11 of 13 (84.6%) bosentan-treated CHF rats been concerned with the intrarenal hemodynamics in CHF remained alive compared with 7 of 11 (63.6%) untreated [22, 23, 25 ]. At a single nephron level, single nephron GFR, CHF rats (P50.067). Chronic blockade of the endogenous glomerular plasma flow (Q ) and glomerular capillary A ET system in CHF rats with bosentan led to a significant ultrafiltration coefficient (K ) are reduced. Single nephron f decrease in LVEDP (from 26.663.3 to 11.462.2 mmHg, FF and glomerular blood pressure (P ) are elevated, the GC P,0.001), without significantly affecting MAP, heart rate latter resulting from the substantial increase in efferent and cardiac contractility (dP/ dt ) ( Table 2 ). This longarteriolar resistance (R ) in CHF produced by myocardial max E term treatment with bosentan also largely reduced the infarction in rats [22, 23, 25] . In CHF rats, the increased increased HW:BW and RV:BW seen in the untreated single nephron FF was associated with augmented oncotic MI-induced CHF rats (Table 1) , but heart weight remained pressure in plasma leaving the glomerulus, thereby favorsignificantly elevated compared to sham-operated rats.
ing enhanced proximal tubular sodium reabsorption [22] . There was no significant difference in infarct size between Thus, the altered glomerular hemodynamics has been bosentan-treated rats and vehicle-treated rats (4162 vs.
thought to be responsible for the common occurrence of 4362%) ( Table 1) .
sodium and fluid retention in CHF. Fig. 1 shows that chronic bosentan treatment signifiThere is considerable evidence for a role of ET in the cantly reduced the markedly elevated RVR in the rats with pathogenesis of renal dysfunction and sodium retention CHF induced by MI (7.760.6 vs. 15.662.5 mmHg / ml / associated with CHF. The known renal vasoconstrictive min, P,0.001). This led to a large increase in RPF and antinatriuretic actions of ET-1 mimic the alterations in (6.160.5 vs. 3.060.3 ml / min, P,0.001), resulting in a renal hemodynamics and sodium excretion in CHF [1,4-significant decrease in filtration fraction (0.26860.0155 vs. 6, 20, 22, 25] . Furthermore, previous studies have docu-0.45460.037, P,0.001) since the increase in GFR was mented high levels of plasma ET-1, and a blunted renal moderate. This chronic treatment also significantly inresponse to ET-1 in animals and humans with CHF creased urinary sodium excretion as measured during [6, 7, [26] [27] [28] . clearance periods (Fig. 1) . Furthermore, the 24-h U V was An elevation in local renal ET-1 concentration has also Na also significantly increased in the bosentan-treated CHF recently been reported in experimental CHF [7, 8] . Acute rats (Fig. 2) as compared with untreated CHF animals ET receptor blockade improves renal blood flow in ex-(0.40760.048 vs. 0.25360.043 mmol / 24-h, P,0.05).
perimental CHF, as measured by Doppler flowmeter [7, 9] .
We recently found that acute ET receptor blockade in kidney function in CHF result from its preferential dilation MI-induced CHF rats with tezosentan reversed the of the efferent glomerular arteriole. Indeed, we have profoundly increased RVR and improved renal plasma previously demonstrated that ET blockade with bosentan flow and sodium excretion [20] . Chronic selective ET largely prevented the increase in R and the fall in K A E f receptor antagonism suppressed plasma atrial natriuretic caused by systemic nitric oxide inhibition [33] . peptide, attenuated the magnitude of sodium retention, and An increase in cardiac output in CHF rats with chronic prevented the decline in creatinine clearance in experimenbosentan treatment could also contribute to the improvetal CHF [12, 13] . However, there are to our knowledge no ment of renal function in CHF by increasing glomerular reports concerning the effect of chronic dual ET / ET perfusion.
A B receptor blockade on the renal alterations associated with Finally, the beneficial effects of prolonged blockade of CHF. Thus, this study was designed primarily to investi-ET receptors on renal function in the MI-induced CHF rats gate the renal responses to prolonged dual ET receptor might also be a consequence of a preventive effect on renal blockade in CHF rats with bosentan. structural changes. Indeed, ET is a very potent profibrotic In the present study, chronic ET receptor blockade with hormone. ET is mitogenic for mesangial cells and induces bosentan largely prevented the severe renal vasoconstricmatrix protein synthesis [3, 29] . It has recently been tion associated with CHF, leading to improvements in reported that chronic bosentan treatment normalizes ex-RPF, GFR, and renal sodium excretion. The natriuretic pression of the collagen I gene and leads to the regression response to chronic bosentan treatment in CHF rats may be of renal vascular fibrosis in experimental hypertension due to removal of its direct stimulatory effect on tubule [34] . sodium reabsorption or may be secondary to inhibition of Other vasoconstrictor systems activated in CHF, such as ET -stimulated aldosterone production [20, [29] [30] [31] . In this the renin-angiotensin system, may likewise contribute to B study, we did not assess the renal effects of bosentan in the renal pathophysiology of the MI-induced CHF rat sham-operated rats. However, in a previous study, acute model. It has been reported that glomerular hemodynamics bosentan administration in normal conscious rats had no in CHF dramatically improved after angiotensin-converting effect on BP, renal plasma flow, or RVR, although an inhibitor [22] . ET-1 and angiotensin II signal through increase in urinary sodium excretion and a small decline in common intracellular pathways [35] , and in fact some of GFR were observed [20] . The findings of the present study the actions of Ang II can be largely prevented by ET suggest that ET is implicated in the pathophysiology of inhibition [36, 37] . Thus it is likely that blockade of both renal vasoconstriction and sodium retention in animal the ET and the renin-angiotensin (RAS) systems would models of CHF.
have synergistic effects. Indeed, it has been reported that Chronic bosentan treatment also markedly decreased blockade of both ET and RAS had additional favorable LVEDP without affecting heart rate and cardiac contractilieffects on cardiac function in experimental CHF [38, 39] ty. Although acute ET receptor blockade has been reported and on glomerular hemodynamics such as R and P in E G C to improve renal blood flow in experimental CHF [7, 9] , rats after acute systemic nitric oxide inhibition [33] . our study is the first to describe the beneficial effects of Vascular smooth muscle (constricting) ET receptors are B long-term blockade of dual ET receptors on whole kidney upregulated in human heart failure, since the vasoconstricfunction and sodium excretory function in the rat model of tion induced by an ET agonist sarafotoxin S6c, is B CHF induced by MI. increased in CHF patients [40] . Similar results are also The precise mechanisms by which chronic bosentan obtained at the level of the coronary circulation in dogs treatment improves whole kidney functions in CHF are as with CHF [41] . The increased cardiac output seen in yet unknown and not directly addressed in this study.
bosentan-treated but not in BQ-123-treated dogs with MI However, our findings of significantly decreased FF by suggests that blockade of ET receptors alone or blockade B bosentan treatment suggest that chronic ET blockade of both ET and ET receptors will be necessary to A B causes complex glomerular hemodynamic changes in CHF improve cardiac function [42] . Furthermore, ET receptors B rats. The decrease in FF might suggest that chronic ET have been reported to stimulate aldosterone production blockade induces a predominant post-glomerular vasodilat- [30, 31] . Further studies will be necessary to clarify the ion. This is consistent with the effect of the dual antagodifference between selective blockade of ET receptors A nists bosentan [32] and tezosentan [10] in the model of and combined blockade of ET and ET receptors on A B
glycerol-induced rhabdomyolysis. Previous reports have cardiorenal hemodynamics in experimental heart failure. shown that the pre-glomerular and efferent arterioles are
The present results offer a promising therapeutic option highly sensitive to the vasoconstrictor effects of ET-1 for the treatment of renal failure in patients with CHF. [3, 4, 29] . Systemic administration of mildly pressor doses However, we cannot directly extrapolate the data to the of ET-1 produces a proportionally greater increase in R clinical condition, since patients with CHF are often E than in R , hence an increase in P [4] . ET can also treated with diuretics, ACE inhibitors and b-blockers, all A G C contract mesangial cells and lower K [3, 4] . Thus, we of which have renal consequences. Bosentan may have a f speculate that the beneficial effects of bosentan on whole different effect when given in addition to these drugs.
endothelin type A receptor antagonism in experimental heart failure.
Nevertheless, the present data suggest that dual endothelin 
